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Background: Diabetic nephropathy (DN) is one of the major causes of end-stage renal disease in diabetic patients.
Increasing evidence from studies in the rodents has suggested that this disease is associated with increased oxidative
stress due to hyperglycemia. In the present study, we evaluated the renoprotective, anti-oxidative and anti-apoptotic
effects of the flavonoid quercetin in C57BL/6J model of DN.
Methods: DN was induced by streptozotocin (STZ, 100 mg/kg/day, for 3 days) in adult C57BL/6J mice. Six
weeks later, mice were divided into the following groups: diabetic mice treated with quercetin (DQ, 10 mg/kg/day,
4 weeks), diabetic mice treated with vehicle (DV) or non-treated non-diabetic (ND) mice.
Results: Quercetin treatment caused a reduction in polyuria (~45%) and glycemia (~35%), abolished the
hypertriglyceridemia and had significant effects on renal function including, decreased proteinuria and high
plasma levels of uric acid, urea and creatinine, which were accompanied by beneficial effects on the structural
changes of the kidney including glomerulosclerosis. Flow cytometry showed a decrease in oxidative stress and
apoptosis in DN mice.
Conclusion: Taken together, these data show that quercetin effectively attenuated STZ-induced cytotoxicity in
renal tissue. This study provides convincing experimental evidence and perspectives on the renoprotective
effects of quercetin in diabetic mice and outlines a novel therapeutic strategy for this flavonoid in the treatment
of DN.
Keywords: Quercetin, Diabetic nephropathy, Oxidative stress, Apoptosis, FlavonoidsIntroduction
Diabetic nephropathy (DN) is one of the most important
microvascular complications of diabetes mellitus [1-3]
and is the largest single cause of end stage renal disease
[4,5], that leads to a decrease in quality of life and an in-
creased risk of mortality [6]. Recent data indicate that
reactive oxygen species (ROS) play a pivotal role in the
pathophysiology of DN [7-9]. Persistent hyperglycemia is
the main determinant of initiation, promotion and sus-
tentation of DN and it contributes to oxidative stress via* Correspondence: evasquez@terra.com.br
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unless otherwise stated.two major mechanisms, augmentation of ROS [7,10-13]
and the attenuation of antioxidative mechanisms through
glycation of antioxidant enzymes [1,12,14].
The development of experimental models of DN has
provided a valid approach to characterize its pathogenesis
and to create new possibilities for the diagnosis and treat-
ment of this disease. In this regard, the pancreatic islet cell
toxin streptozotocin (STZ) has been widely used to induce
diabetes in rodents [1,15,16], mainly in rat models. Like-
wise in rat models, the mouse has become attractive
for the understanding of human diseases due to the simi-
larities in physiology and to the advantage that its genome
can be easily manipulated [17] to produce models of com-
plex genetic diseases such as atherosclerosis [18-20], which
is not commonly developed in rats.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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oxidative stress may play a crucial role in the pathogenesis
of DN [21,22], antioxidant therapy has shown conflicting
results during the treatment of DN in diabetic patients
[23]. Currently, only blockers of the renin-angiotensin
system are chronically used; however, there are limita-
tions of this mechanism [23,24] which justifies the search
for effective and safer antioxidant candidates. The flavo-
noids are plant phenolic compounds that exhibit strong
antioxidant properties and are widely distributed through-
out the plant kingdom; thus, flavonoids are a therapeutic
option [25,26].
Quercetin is a bioflavonoid found in red wine and
numerous fruits, vegetables, and nuts [27,28]. Recently,
biochemical and pharmacological studies of quercetin
have shown that it is a potent scavenger of ROS and
possibly reduces the risk of cardiovascular and renal dis-
eases [1,28-30]. However, its effects on kidney function,
excessive ROS production and kidney cell apoptosis, that
are supposed to occur in this mouse model of DN, have
not yet been evaluated. Therefore, the present study was
designed to test the hypothesis that quercetin presents
nephroprotective effects on the main parameters that
characterize the DN. We focused our model in the
C57BL/6J, which has been the most used genetic back-




Eight-week-old homozygous C57BL/6J mice were obtained
from the Laboratory of Translational Physiology, Health
Sciences Center, at the Federal University of Espirito
Santo, Brazil. Animals were housed at room temperature
(22°C) in a humidity-controlled environment with a 12-h
light/12-h dark cycle in the Experimental Unit of the La-
boratory of Translational Physiology. Mice were allowed
free access to water and a standard laboratory chow diet
(Labina®) until experiments were performed. The animals
were studied according to the principles devised by the
National Institute of Health (NIH) Guide for the Care and
Use of Laboratory Animals and the protocol was previ-
ously approved by the Institutional Ethics Committee for
the Use of Animals (CEUA, Protocol # 013/2010).
Experimental protocol
Mice were rendered diabetic by intraperitoneal injection
of STZ (Boehringer-Mannheim, Mannheim, Germany)
diluted in citrate buffer (10 mM, pH 4.5) at a dose of
100 mg/kg/day for 3 days, The control group (non-dia-
betic, ND, n = 10) was administered an equivalent vol-
ume of the vehicle citrate buffer. One week after STZ
injection, glycemia was measured after 6 hours of food
deprivation and animals with glucose levels greater than250 mg/dL for at least 2 days were considered diabetic.
Six weeks after STZ injections, diabetic mice were ran-
domly divided and received either no treatment (vehicle
soy oil, DV, n = 10) or oral quercetin (DQ, n = 10) at a
dosage of 10 mg/kg per day for 4 weeks. This dosage was
based on previous studies with hypertensive and diabetic
animals [31,32].
Metabolic and biochemical parameters
After STZ injection, all animals were weighed once a
week. At week 4, the animals were housed for a 24-hour
period in individual metabolic cages for adaptation. Fol-
lowing this period, a known volume of water and quan-
tify of food were placed in the drinking bottles and the
feeder, respectively. After 24 hours, the volume of liquid
and chow remaining in the cages were measured. Urine
was collected and its volume and protein concentration
was determined. Animals were euthanized via an overdose
of thiopental (Cristalia, Sao Paulo, Brazil, 200 mg/kg, i.p.)
after a period of food deprivation, and their blood was col-
lected for glucose, creatinine, cholesterol, triglycerides,
urea and uric acid measurements using colorimetric kits.
Proteinuria was determined by a Bradford assay [33]. Tis-
sues were perfused with cold phosphate-buffered saline
(PBS, pH 7.4, 0.1 mol/L) through the left ventricle and the
kidney was fixed in Duboscq-Brazil solution for histo-
logical evaluation.
Kidney histology
After perfusion, the mouse kidneys were rapidly fixed
with Duboscq solution, weighed and processed for mor-
phometric and histological analyses. Samples were dehy-
drated with a graded series of alcohols, embedded in
paraffin, sectioned into 3-μm-thick slices and stained
with hematoxylin and eosin for light microscopic mor-
phological studies (AX70, Olympus, Center Valley, PA,
USA). Images were captured at a 40x magnification with a
color video camera (VKC150, Hitachi, Tokyo, Japan) con-
nected to a microscope (AX70, Olympus, Center Valley,
PA, USA). All morphometric and histological analysis
were performed in a blinded manner. The mean glomeru-
lar tuft area of each kidney was obtained by calculating
the mean value of 30 individual glomeruli measured by
Image J software (version 1.33u, Public Domain). Masson’s
trichrome staining was used to quantify glomerulosclerosis.
A total of 30 glomeruli were used to calculate the percent-
age of the stained area for each kidney using the Image J
program (Public Domain Image Processing Program,
National Institutes of Health, Bethesda, MD).
Measurement of intracellular superoxide anions by flow
cytometry
Fractions enriched for kidney cell were obtained from
each of the groups, were prepared based on previous
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was grossly minced using surgical scissors and was incu-
bated in an isolation solution containing collagenase type
II (Gibco Life Technologies, Sao Paulo, SP, Brazil) to dis-
sociate the cells. The cell suspension was filtered through
a nylon screen (BD Falcon 70 μm) to remove cellular deb-
ris. The samples were then washed twice in PBS before
further analysis. Dihydroethidium (DHE, 160 μM) was
added to cell suspensions (106 cells) which were then in-
cubated at 37°C for 30 min in the dark in order to deter-
mine the intracellular production of superoxide anions
(•O2
−) [34-36]. DHE is freely permeable to cells and is
rapidly oxidized to ethidium, which binds to DNA and
results in the amplification of a red fluorescence signal.
Samples were treated with 10 mM doxorubicin for 5 min
to induce oxidative stress in the absence of cell toxicity;
these samples served as positive control. Cells incubated
with ethanol served as the negative control. Cells were
then washed, resuspended in PBS, and maintained on ice
for immediate detection via flow cytometry (FACSCanto
II, Becton Dickinson, San José, CA, USA). Data were
analyzed using FACSDiva software (BD Company), and
overlay histograms were constructed using FCS Express
software. For DHE fluorescence quantification, samples
were acquired in duplicate, and 10,000 events were ob-
tained for each measurement. Red fluorescence was de-
tected between 564 and 606 nm using a 585/42 bandpass
filter. Data are expressed as the geometric mean fluores-
cence intensity.
Apoptosis
Apoptotic kidney cells were quantified via annexin V-
fluorescein isothiocyanate (FITC) and propidium iodide
(PI) staining, using a commercial detection kit (Becton
Dickinson, San José, CA, USA). Briefly, renal cells were
washed twice with PBS and the final volume was adjusted
to 500 μl with binding buffer (5 × 105 cells). Then, 2 μl of
annexin V–FITC and 2 μL of PI were added to the solution
and the cells were gently vortexed. Cells were then incu-
bated for 15 min at room temperature (25°C) in the dark.
Finally, cells were analyzed using a FACSCanto II flow cyt-
ometer (BD). Apoptosis was quantified by analysis of the
flow cytometry data after annexin V-FITC and PI labeling.
Kidney cells that were annexin V-FITC−/PI+ were classi-
fied as damaged (Q1). Cells that were annexin V-FITC+/PI+
were considered to be late apoptotic or secondary apop-
totic cells (Q2). Cells that were annexin V-FITC−/PI− were
considered live cells (Q3). Cells that were annexin V-FITC+/
PI− were classified as early or primary apoptotic cells
(Q4) [37].
Statistical analysis
All data are expressed as the means ± SEM. The
Kolmogorov-Smirnov test showed that variables had anormal (Gaussian) distribution. Flow cytometry data of
ROS production are expressed as the geometric MFI–
variation coefficient of two repeated and statistically repro-
ducible measurements of at least 5 independent animals
(the Friedman test). The statistical analysis was performed
by one-way analysis of variance (ANOVA). When the
ANOVA showed significant differences, the Tukey’s test
was applied as a post hoc analysis. The differences were
considered significant when p < 0.05.
Results
Metabolic parameters
Figure 1 summarizes the general physical characteristics,
diuresis, and food and water intake, 10 weeks after the in-
duction of diabetes. Diabetic mice exhibited hyperphagia
(5.0 ± 0.5 g/day, Figure 1A) and polydipsia (25 ± 2 mL/
24 h, Figure 1B) when compared to non-diabetic mice
(3.0 ± 0.26 g/day and 5.0 ± 0.6 mL/24 h). Quercetin treat-
ment did not show a significant effect on food and water
intake. Diabetic mice exhibited a severe polyuria (24 ±
2 mL/24 h, Figure 1D) when compared to non-diabetic
mice (1.9 ± 0.2 mL/24 h), and this parameter was reduced
by approximately 46% in diabetic mice treated with quer-
cetin. Body weight was similar among the 3 groups; however,
over the 2-week period, body weight gain in the non-
diabetic group (28% g, p < 0.05) neither the diabetic mice
nor the diabetic mice treated with quercetin exhibited sig-
nificant body weight gain (+0.6 ± 1.2 and +1.2 ± 1.0 g, re-
spectively, Figure 1C).
Biochemical parameters
As expected, the results summarized in Figure 2 show that
diabetic mice exhibited a significant increase in plasma
glucose (3-fold), total cholesterol (1.7-fold) and triglycer-
ides (1.7-fold) levels when compared to non-diabetic mice
(135 ± 9 mg/dL, 78 ± 2 mg/dL and 64 ± 6 mg/dL, respect-
ively). Treatment with quercetin caused a significant at-
tenuation of plasma hyperglycemia (35%) and failed to
reverse the hypercholesterolemia; however, it diminished
the hypertriglyceridemia to levels of 34 ± 6 mg/dL, which
was 50% lower than levels observed in the non-diabetic
mice.
Renal function parameters
Figure 3 summarizes the mean values of the parameters
used as indices of renal function. Diabetic mice exhibited
significantly high plasma concentrations of uric acids
(~3-fold, Figure 3A), urea (25%, Figure 3B) and creatinine
(42%, Figure 3C) when compared to non-diabetic ani-
mals (0.6 ± 0.15 mg/dL, 70 ± 3.00 mg/dL and 0.24 ±
0.02 mg/dL, respectively, p < 0.05). Quercetin showed a
tendency to reduce the hyperuricemia and significantly
reduced the levels of plasma creatinine and urea levels to
values similar to those observed in the non-diabetic group
Figure 1 Food (A) and water (B) intake, body weight gain (C) and urine volume (D) in diabetic mice treated with quercetin (DQ) compared
to diabetic mice administered vehicle (DV) and non-diabetic (ND) mice. Values are means ± SEM for n = 6–8 mice per group. *p < 0.05 vs. ND,
#p < 0.05 vs. DV.
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in non-diabetic mice and was significantly reduced
in diabetic mice (34%); however, creatinine clearance
returned to normal levels upon treatment with quer-
cetin (Figure 3E). Proteinuria, which is another index
of renal function, was significantly increased (~3-fold, p <
0.05, Figure 1D) in the diabetic mice when compared to
non-diabetic mice (4.0 ± 0.4 mg/24 h, p < 0.05). Treatment
with quercetin tended to reduce levels of proteinuria, but
these levels were still significantly higher than those ob-
served for non-diabetic mice (Figure 3D).
Kidney morphometric parameters
Diabetes was associated with an increase of approximately
18% in kidney weight/body weight ratio when compared
to non-diabetic mice (13.2 ± 0.3 mg/g, p < 0.05), whereas
quercetin attenuated this diabetic effect (Figure 4A). The
glomerular tuft area analysis of each kidney demonstrated
a significant increase of approximately 30% in diabetic
mice when compared to non-diabetic mice and quercetinFigure 2 Plasma glucose (A), total cholesterol (B) and triglycerides (C) in
mice administered vehicle (DV) and non-diabetic (ND) mice. Values are mshowed a tendency to attenuate this glomerular injury
(Figure 4B). As illustrated in the typical photomicro-
graphs (Figure 4D), glomerulosclerosis, appeared more
often in the diabetic mice which was characterized by
a deposition of extracellular matrix in the mesangium
and by glomerular hyperplasia, was more important
in the diabetic than in the non-diabetic mice and
quercetin had a beneficial effect on this parameter (4C).
On average, diabetic animals showed a significant in-
crease in the glomerular tuff area (30%, p < 0.05) and in
the occurrence of glomerulosclerosis (~3-fold, p < 0.05)
when compared to the non-diabetic mice (2517 ± 124 μm2
and 23 ± 1.2%, respectively), and diabetic mice treated with
quercetin showed values similar to those observed in non-
diabetic mice.
Oxidative stress
We evaluated ROS production using flow cytometry and
DHE to quantify the generation of superoxide anions
(•O2
−); the presence of this compound is indicated bydiabetic mice treated with quercetin (DQ) compared to diabetic
eans ± SEM for n = 6–8 mice per group. *p < 0.05 vs. ND, #p < 0.05 vs. DV.
Figure 3 Plasma uric acid (A), urea (B), creatinine (C), proteinuria (D) and creatinine clearance (E) in diabetic mice treated with
quercetin (DQ) compared to diabetic mice administered with vehicle (DV) and to non-diabetic (ND) mice. Values are means ± SEM for
n = 6–8 mice per group. *p < 0.05 vs. ND, #p < 0.05 vs. DV.
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Typical histograms obtained via flow cytometry analysis
show a rightward-shift in the log DHE fluorescence in dia-
betic mice (Figure 5A) when compared to non-diabetic
mice and diabetic mice treated with quercetin. As summa-
rized in Figure 5B, we observed a remarkable increase in
the levels of •O2
− in DV animals (56%) when compared to
ND mice (1524 ± 81 a.u., p < 0.05). Quercetin treatment
significantly reduced the levels of oxidative stress to levels
similar to those observed in ND mice.
Apoptosis
One aim of this study was to evaluate the viability of kidney
cells using PI and annexin V staining via flow cytometryFigure 4 Kidney weight/body weight ratio (A), glomerular tuff area (B
(DQ) compared to diabetic mice administered with vehicle (DV) and n
areas from each kidney were used to calculate the glomerular tuff area and
sections (magnification of 400x) stained with Masson trichrome to identify
n = 6–8 mice per group. *p < 0.05 vs. ND, #p < 0.05 vs. DV.analysis. Although the percentage of viable kidney cells
was significantly decreased in diabetic mice, greater than
95% of the kidney cells obtained from the three groups of
animals were viable which provided excellent conditions
for the evaluation of apoptosis (Figure 6B). Typical histo-
grams (Figure 6A) show that DV animals exhibited greater
percentage of kidney cells in the early apoptosis quadrant
(Q4: annexin V+/PI−), in the late apoptosis quadrant (Q2:
annexin V+/PI+) and in the damaged cell quadrant (Q1:
annexin V−/PI+). In contrast, the number of cells in the
quadrants Q4, Q2 and Q1 was markedly reduced for mice
treated with quercetin. Figure 6C summarizes the percent-
age of cells in early and late apoptosis. Diabetic animals
(DV) showed a marked increase in the percentage of cells), glomerulosclerosis (C) in diabetic mice treated with quercetin
on-diabetic (ND) mice. The mean value of 30 individual glomeruli
glomerulosclerosis. Micrographs (D) are representative glomerular
sclerosis (blue) in each glomerulus. Values are means ± SEM for
Figure 5 Production of superoxide anions. A: representative
histograms from flow cytometry analysis using dihydroethidium
(DHE) in diabetic mice treated with quercetin (DQ), compared to
diabetic mice that received the vehicle (DV) and non-diabetic
(ND) mice; the log fluorescence (X-axis) shows the intensity of
fluorescence (+) for the number of kidney cells assayed. B: bar
graph shows geometric mean fluorescence intensity. *p < 0.05 vs. ND
group, #p < 0.05 vs. DV group.
Gomes et al. Lipids in Health and Disease 2014, 13:184 Page 6 of 10
http://www.lipidworld.com/content/13/1/184in early (4-fold) and late apoptosis (6-fold) when com-
pared to non-diabetic (ND) mice (1.58 ± 0.35% and 0.46 ±
0.15%, respectively). Treatment of diabetic (DV) mice with
quercetin (DQ) had a marked effect on the progression
from early to late apoptosis (Figure 6C). Quercetin treat-
ment tended to reduce the high levels of early apoptosis,
but quercetin was able to decrease the percentage values
to levels similar to those observed in non-diabetic animals.
Discussion
This work showed that chronic oral treatment with low-
dose quercetin exerts antidiabetic effects and attenuates the
development of nephropathy in STZ-induced DN mice.
These results are supported by a decrease of plasma glu-
cose, creatinine, triglycerides, proteinuria and diminution of
mesangial matrix expansion accompanied by a reduction
in •O2
− production and apoptosis in kidney cells.
STZ-injected mice exhibit destruction of β cells and re-
duction in insulin secretory capacity [15,38]. Consequently,these mice develop typical characteristics of diabetes such
as polydipsia, polyuria, and proteinuria accompanied by
loss of body weight (even with polyphagia) as observed in
the present study. Furthermore, in accordance with our
biochemical and morphological data, we considered the
five stages of clinical classification of DN [39,40] and sug-
gest that this experimental murine model corresponds to
a stage 4 clinical classification due to its declining glom-
erular filtration rate and proteinuria; thus, this model is
suitable for evaluating the nephroprotective effects of the
bioflavonoid quercetin. It must be noted that we avoided
interfering with the intrinsic nephrotoxic effects of STZ
by acquiring our data 6 weeks after STZ administration
when the kidneys are known to have recovered from the
acute renal injury caused by STZ [38,41,42]; thus, we can
assume that the damages observed in our model was due
only to diabetic status.
Interest in studies of the effects of natural antioxidants
prevent oxidative damage in mouse models of diabetes has
recently grown [2,38,43]. The best candidates are generally
molecules that show high power antioxidant capacity, high
permeability to mitochondrion [44], long half-lives [45]
and enhancement of enzyme activity [43]; quercetin ex-
hibits all of these traits. This bioflavonoid may inhibit the
formation of ROS in the three different ways: (a) by inter-
acting directly with •O2
− during initiation, (b) by forming
hydroxyl radicals via the chelation of iron ions, and (c) by
directly reacting with lipid peroxyl radicals scavengers
during lipid peroxidation [46]. Additionally, it is possible
that quercetin increases the activity of superoxide dis-
mutase, catalase, glutathione peroxidase, glutathione reduc-
tase and glutathione [43,47]. All these effects may promote
radical scavenging activity, anti-inflammatory and anti-
apoptotic effects and contribute to renal protection against
STZ-induced DN.
Recent data has shown that the persistent hyperglycemia
leads to an increase in the activity of several pathways in-
volved in the disease that contribute to oxidative stress:
(1) auto-oxidation of glucose, (2) advanced glycation
end-product (AGE) formation, (3) polyol pathway flux,
(4) protein kinase C (PKC) isoforms activation and (5)
mitochondrial dysfunction [5,10,48-50]. Our results dem-
onstrate that quercetin attenuates hyperglycemia in ac-
cordance with some authors [46,51-54], however, other
authors disagree [1,43]. Independent of this apparent
inconsistence, the impact on glycemia may be due to per-
turbations of some pathways. Previous studies have shown
that this bioflavonoid can protect pancreatic β-cells from
oxidative stress and damage (either directly or indirectly)
and improve insulin secretion in STZ models [51,53]. Add-
itionally, quercetin can stimulate glucose uptake in per-
ipheral tissues via the translocation of GLUT4 [46,55,56]
and can increase hepatic glucokinase activity [53], thus
augmenting both oxidation and storage of glucose and
Figure 6 Flow cytometric analysis of apoptosis in kidney cells. Each dot plot (A) was constructed using propidium iodide (PI) and annexin
V/FITC staining indicating: damaged cells (Q1), cells that are undergoing late apoptosis (Q2), viable cells (Q3) and cells in early apoptosis (Q4).
Bar graph B shows the average percentage of PI positive (viable) cells, which were used to quantify apoptosis. Bar graph C shows the
average percentage of cells in early and late apoptosis in non-diabetic mice (ND), diabetic mice administered vehicle (DV) and diabetic mice treated
with quercetin (DQ). Values are mean ± SEM for 6 to 8 animals per group. *p < 0.05 vs. ND group and #p < 0.05 vs. DV group.
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Moreover, it has been reported that quercetin can block-
ade α-glucosidase activity in vitro [57,58] and in vivo [53],
thus inhibiting the digestion and absorption of carbohy-
drates in the small intestine [59]. In our study, this latter hy-
pothesis provide a better explanation for the hypoglycemic
effect exhibited by quercetin, considering that it exhibits
low bioavailability via oral administration due to poor
solubility and stability [25]. Therefore, we cannot dis-
card the notion that indirect effects of quercetin on
oxidative stress are responsible for the improvement
in glycemic homeostasis, as recently observed in a
mouse model by Alam et al. [56].
It has been shown that decreases in body weight are due
to intense dehydration and catabolism of fats and proteins,
even under the polyphagia and polydipsia evident condi-
tions observed in the DN group [43,60]. This hypothesis is
supported by the observation that hypertriglyceridemia
and, in part, azotemia occurs in diabetic animals. Quer-
cetin treatment was capable of reducing polyuria and fat
and protein levels, likely as a consequence of better control
of the glycemic state which leads to lower release of fatty
acids from adipose tissue and normalizes triglycerides
plasma levels without modifying the hypercholesterolemia;
these results are similar to those observed by others [11].
It should be noted that, since this flavonoid may decrease
LDL and increase HDL [61,62], we cannot discard the
possibility of alteration in the ratio HDL/LDL, maintaining
the hypercholesterolemia invariable. Moreover, the dose
we used in the present study (10 mg/Kg) was unable toimprove body weight, which conflicts with another report
[43]. This apparent contradiction could be due to different
types of experimental rodent models, the use of higher
doses (from 2.5- to 10-fold) or the route of administration
(e.g., intraperitoneal), which could increase the bioavail-
ability of quercetin as observed by others [38,63-65].
Our data corroborate the hypothesis that links renal
dysfunction to renal oxidative stress and is in agreement
with other reports [1,56]. Under pathologic conditions of
oxidative stress, the increased production of ROS could
compromise NO bioavailability and promote the forma-
tion of a variety of vasoconstrictive mediators that could
affect renal functions, such as tissue perfusion and glom-
erular filtration [1,24,42]. These changes could contrib-
ute to increases in serum creatinine, urea and uric acid,
accompanied by a reduction of creatinine clearance and
proteinuria, as observed by us and by others [66,67]. It is
likely that the antioxidative properties of quercetin de-
creases the production of vasoactive autacoids, which
may play a role in its improvement of renal dysfunction
in diabetes. This hypothesis is further supported by re-
ports that quercetin produce a direct vasorelaxant effect
in vascular tissues [68-70]. Furthermore, the glomerulus
is considerably more sensitive to oxidative injuries than
other nephron segments [70]. This and the above factors
could explain our finding regarding the improvement in
creatinine clearance in the DN group treated with quer-
cetin, despite the absence of the normalization of other
renal parameters. It should be emphasized that urea and
uric acid can be generated by amino acid and purine
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excreted by tubular secretion [66,67].
In addition to the biochemical parameters, our mor-
phological data also demonstrate that quercetin exhibits
a nephroprotective effect. In diabetic mice, we observed
a significant increase in glomerular tuft size and glomer-
ulosclerosis indicating an early diabetes-induced renal
injury; these results are in agreement with other reports
[5,21,32,67,71]. The novelty of the present study is that
treatment with quercetin resulted in a significant amelior-
ation of the observed glomerulosclerosis and the kidney
weight/body weight ratio, most likely due to the hypoglycemic
effect discussed above in addition to its direct antioxida-
tive properties. Oxidative stress plays a major role in the
disruption of cellular functions in the kidney and leads
to increased vascular permeability and tissue damage [6].
This hypothesis is supported by the finding of others
[11,43] showing evidence of renal oxidative stress in dia-
betic rats [38,63-65].
In support of this oxidative stress hypothesis, flow cy-
tometry assessment of dihydroethidium (DHE) fluores-
cence showed that the increased levels of •O2
− in the
kidneys of diabetic mice was reduced by quercetin treat-
ment and resulted in the abolishment of ROS (Figure 5).
This finding corroborates the concept that the overpro-
duction of •O2
− is implicated in the pathophysiology of
diabetic nephropathy and that this flavonoid is a potent
scavenger of ROS that could potentially reduce the risk
of related diseases [29,30,46,54,56,72,73]. Moreover, oxi-
dative stress is recognized as a strong mediator of apop-
tosis [43,54,74]. Our flow cytometry data show, for the
first time that DN in this mouse model is accompanied
by apoptosis, indicating a marked effect of this disease
on kidney cell function. Interestingly, quercetin treat-
ment was able to greatly ameliorate the onset of both
early and late apoptosis in diabetic mice and to restore cell
viability. Our data corroborate the findings of Liu et al.
[75] who observed lower ROS production and apoptosis in
kidneys damaged by lead when treated with the same bio-
flavonoid; these results are in agreement with others who
reported that quercetin possesses anti-apoptotic properties
[54,76,77]. In contrast, high levels of quercetin increased
the number of dead kidney cells, indicating the presence of
dose-dependent auto-oxidative activity followed by inhib-
ition of mitochondrial respiration which affect ROS pro-
duction [43,78]. Therefore, our data contribute to a better
understanding about the potential use of quercetin as an
antioxidant in a dose-dependent manner.
Although other studies have tested the effects of quer-
cetin on the DN rat model, it should be considered that
the common route of administration has been via intra-
peritoneal [43,46,54,63]. On the other hand when quer-
cetin is administered via oral [38,64,65], the dose has
been much higher (25 to 100 mg/Kg) than that we usedin the genetic background C57BL/6J mouse. The import-
ance of our data is that we found beneficial effects, in-
cluding a decreased oxidative stress and anti-apoptotic
effect, both detected by direct measurements, even using
a lowest relative bioavailability oral dose of quercetin (10
mg/Kg). Thus, these additional data highlight the im-
portance of quercetin as potential nutraceutical for man-
agement of DN.
In conclusion, our results were obtained from the most
commonly used mouse genetic background (C57BL/6J)
and suggest that oxidative stress plays a pivotal role in the
pathophysiology of DN and that oral low-dose quercetin
exhibits a beneficial effect by ameliorating the conse-
quences of hyperglycemia-induced ROS overproduction
in the kidney. Thus, quercetin is a promising therapeutic
agent that could potentially be used for the prevention
and/or treatment of renal dysfunction caused by diabetes.
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